Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Will Not Rule Out Symbicort In 2022 As Trial Looms

Q1 Investor Presentation Offers A More Conservative Approach

Executive Summary

Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.

You may also be interested in...



Viatris Slashes Full-Year Revenue Guidance By $800m

Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.

What’s Next? Five Things To Look Out For In August

A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.

Can The Pipeline Soothe A US Generics Pricing Headache?

Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel